Heart disease is the world’s number 1 killer.
Imagine if a company discovered a cure for heart disease, we did!

Our company (established 2018) has been supplying an over the counter treatment for 5 years that reverses heart disease, with thousands of patients world-wide.

This is not a typical early-stage biotech investment. We are a revenue-generating company with a proven product, positioned for exponential growth.

• Proven Human Efficacy: Real-world data and pilot studies demonstrate a remarkable 92% success rate in plaque regression.
• Established Revenue: CAVADEX® has been in production and selling worldwide for over five years.
• Safety Assured: The active ingredient is already FDA-approved (GRAS) with a long-established, non-toxic safety profile.
• Immediate Scalability: Robust, proven manufacturing infrastructure capable of immediately scaling to $25 Million USD in weekly revenue from a single site.

Capturing just 10% of the US market is worth over $3.15 Billion USD per MONTH!

Validated by a landmark peer-reviewed study published in Cardiology Research and Cardiovascular Medicine (August 2025), CAVADEX® actively dissolves arterial plaque and dangerous cholesterol crystals at the source.
"It's the greatest advance that we have had in cardiovascular pharmacology... since the statins came on the scene." — Professor Laurie Howes, MB BS PhD FRACP FCSANZ (40+ years in Cardiovascular Pharmacology)

Where to from here?
Everything is in place, we have a proven product, manufacturing, huge market potential... all we need to do now is expedite clinical trials and unlock global market dominance.
Our compound is already FDA approved. We now need to apply for an FDA indication that our product reverses heart disease. This is just a formality, we are seeing plaque reduction and calcium scores drop every day with our existing customers.

We will have our trial results within 6 months, resulting in our company valuation expected in the Billions!

This isn’t just an investment opportunity, it’s an opportunity to participate in a medical revolution that will save millions of lives world-wide.

The Opportunity

We are offering equity in our company for this pivotal, limited funding round.
$100,000 per 1% share. Limited round up to $2 million (20% equity) to fund trials and ignite global dominance.

This is a rare opportunity to generate exceptional returns while funding the most significant revolution in cardiovascular health in a generation.

Own a substantial equity share in a potentially multibillion-dollar company.
Request the Business Brief and scientific documentation today.